As IDO-1 introduces tumoral immune resistance, IDO-1 inhibitors exert anti-tumor immunity by activating the CD8+ cytotoxic T cell and inhibiting the differentiation of suppressor cells such as regulatory T cells [238,239,240]. The gene discussed is IDO1; the disease is neoplasm.